Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MED1 |
| Gene Name: | MED1 |
| Protein Full Name: | Mediator of RNA polymerase II transcription subuni |
| Alias: | Mediator complex subunit 1; Mediator of RNA polymerase II transcription subunit 1: Mediator complex subunit 1: Peroxisome proliferator-activated receptor-binding protein: Thyroid hormone receptor-associated protein complex 220 kDa component: Thyroid receptor-interacting protein 2: p53 regulatory protein RB18A: Vitamin D receptor-interacting protein complex component DRIP205: Activator-recruited cofactor 205 kDa component |
| Mass (Da): | 168478 |
| Number AA: | 1581 |
| UniProt ID: | Q15648 |
| Locus ID: | 5469 |
| COSMIC ID: | MED1 |
| Gene location on chromosome: | 17q12 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20357 |
| Percent of cancer specimens with mutations: | 0.96 |
| Found in amplified chromosomal regions in human cancers: | Breast Cancers. |
| Normal role description: | MED1 is a component of the mediator complex which is targeted to gene promoters bound by regulatory transcription factors and functions as a scaffold for assembly of RNA polymerase II to initiate transcription. MED1 can interact with many nuclear receptors including estrogen and thyroid hormone receptors to facilitate transcription of target genes. MED1 also has a role in regulating apoptosis through its interaction with p53 to promote its activity. MED1 overexpression has been detected in 50% of primary breast cancer cell lines and may function as an oncogene in cancer development. Mis-sense mutations of MED1 found in cancer have not been well characterized. |
| Commentary on involvement of protein in cancer: | Less than 3% mutations in breast, kidney and lung cancer. |